Hyperfine (HYPR) Asset Writedowns and Impairment (2021)

Hyperfine (HYPR) reported Asset Writedowns and Impairment of $56000.0 for Q4 2021, up 500.0% quarter-over-quarter from -$14000.0 in Q3 2021.

Hyperfine (HYPR) Asset Writedowns and Impairment (2021) Analysis & Trends

Hyperfine has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $56000.0 in Q4 2021.

For the quarter ending Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $56000.0; the trailing twelve-month figure through Sep 2022 stood at $56000.0 (changed N/A YoY), and the FY2021 full-year result was $75000.0, down 64.79% from the prior year.
Asset Writedowns and Impairment for Q4 2021 stood at $56000.0, up from -$14000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $75000.0 in Q1 2021, with the low at -$42000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Hyperfine	133.84 Mn	92.56 Mn	1.98 Mn

Download Data